Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceHKSE:03681 -3.57%29 Quick Ratio is 1.91 as of Dec. 2025, which is at its 10-year median of 1.91. GuruFocus rates HKSE:03681 with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, SinoMab BioScience ranks worse than 74.01% on this metric.
SinoMab BioScience (HKSE:03681) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
SinoMab BioScience Quick Ratio Related Terms
SinoMab BioScience Quick Ratio Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03681 vs VRTX, REGN, MRNA: Quick Ratio Comparison
For the Biotechnology subindustry, SinoMab BioScience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
SinoMab BioScience's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (HKSE:03681) has a Quick Ratio of 1.91 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SinoMab BioScience and its competitors. This is near median its historical median of 1.91. Over the past decade, SinoMab BioScience's Quick Ratio has ranged from 0.69 to 15.89. According to the industry distribution chart, SinoMab BioScience ranks #1042 out of 1408 companies in the Biotechnology industry, placing it in the top 74%.
Is SinoMab BioScience's Quick Ratio too high?
SinoMab BioScience's current Quick Ratio of 1.91 is near median its 10-year median of 1.91. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 15.89. The Biotechnology industry median Quick Ratio is 3.59. SinoMab BioScience's value of 1.91 is 46.7% below this industry median. Based on the distribution chart, SinoMab BioScience ranks #1042 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SinoMab BioScience has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #1042 out of 1408 companies for Quick Ratio. This places SinoMab BioScience in the lower half of its industry. The industry median Quick Ratio is 3.59. SinoMab BioScience's value of 1.91 is 46.7% below this benchmark. Historically, SinoMab BioScience's own Quick Ratio has ranged from 0.69 to 15.89 over the past decade. While the company's 10-year median is 1.91 vs. the industry median of 3.59, SinoMab BioScience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SinoMab BioScience's current Quick Ratio of 1.91 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SinoMab BioScience and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current Quick Ratio is 1.91, which is near median its own 10-year median of 1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (HKSE:03681) has a current Quick Ratio of 1.91. The current Quick Ratio is 1.91, which is near median its 10-year median of 1.91 and 46.7% below the Biotechnology industry median of 3.59. SinoMab BioScience's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For SinoMab BioScience (HKSE:03681), the current Quick Ratio is 1.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
29GF Score
Get the complete analysis for HKSE:03681
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03681 has been successfully added to your 
